| Factor Information | |
|---|---|
| Data ID | 2338 |
| Factor | caesarean delivery rate |
| Description | The caesarean delivery rate was 43% compared to our institution average of 27% over the same period (p = 0.02) Figure 1 shows the caesarean delivery rate over the 12-year study period. The overall caesarean delivery rate was 43% in the study cohort, compared with our institutional average of 27% over the same period (p = 0.02). |
| Biomarker | NA |
| Classification | A12 (clinical factor - treatment) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | a predominance of neuraxial anaesthetic techniques, increased caesarean and operative delivery rates, and favourable maternal and neonatal outcomes. Multicentre studies and registries to compare anaesthetic and obstetric management strategies further and delineate risk factors for adverse outcomes are required. |
| p Value | 0.02 |
| Conclusion | We observed a predominance of neuraxial anaesthetic techniques, increased caesarean and operative delivery rates, and favourable maternal and neonatal outcomes. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 148 |
| CHD Type | NA |
| CHD Subtype | NA |
| Reference | |
|---|---|
| PMID | 23121251 |
| Year | 2013 |
| Title | Peripartum outcomes and anaesthetic management of parturients with moderate to complex congenital heart disease or pulmonary hypertension |
| Sample | ||
|---|---|---|
| Population | pregnant woman | |
| Source | all pregnancies occurring in women with a diagnosis of moderate to complex congenital cardiac disease during the period from 1 January 2000 to 31 December 2011 at Lucile Packard Children’s Hospital (LPCH), | |
| Region | Stanford, USA | |
| Method | a retrospective cohort analysis | |
| Race | Cucasian/Hispanic/Asian/Black | |
| Disease History | N/A | |
| Treatment History | Neuraxial analgesia or anaesthesia | |
| Group | study cohort(CHD and or PAH)(Treatment) | author's institutional cases(Control) |
| Number | 65 | N/A |
| Age | 30 ± 7 years | N/A |
| Gender (Male: Female) | 0:65 | Female |
| Marker Level | 0.43 | 0.27 |
